Non-prescription availability of low-dose codeine products

The number of overdoses and opioid-related deaths in Canada is a very serious matter. Health Canada is proposing changes to the Controlled Drugs and Substances Act that would require that all products containing codeine be sold only pursuant to a prescription.

CSHP members are invited to provide comments on the potential risks, benefits, and impacts of the proposed change. More information about the proposed changes are found in the Canada Gazette, Part I Notices and Proposed Regulations. Please note that this consultation is different from the consultation conducted by Health Canada in the summer. The previous consultation was related to proposed changes to the Food and Drug Regulations (Opioids) and would permit the Minister of Health "to add or amend terms and conditions to an authorization for the sale of an opioid."

Please send your comments to Cathy Lyder (Director, Members and Programs) at clyder@cshp.ca, no later than November 3, 2017. All feedback will be collated and forwarded to Health Canada, without identifying the person or organisation who provided the comments.